ThrombHaemost 2008; 100: 154-155 M idgestationalp lacental haemorrhage threatens both mothera nd fetus. Reconciling maternal haemostasis with fetal well-being is amajor therapeutic challenge. Between 24 and 26 weeks gestation in particular, despite aggressive obstetric and neonatal management, fetal survivalisuncertain and survivormorbidity considerable(1).
Case report A42-year-old gravida 6para 5was referred at 24 +5 weeks gestation for persistent vaginal haemorrhage since week 9. Admission haemoglobin (Hb) was7.7 g/dl. Cardiovascularstatus was stable despite ongoing heavybleeding;transfusion of twounits of packedred blood cells increased the Hb to only8.1 g/dl. Personaland familyhaemorrhagicand thromboembolic historywas negative;n oa ntiplatelet drugs had beent aken (plateletc ount: 291 G/l). There were no risk factorsfor,nor aprevioushistoryof, placental abruption. Fibrinogen levels and prothrombinand activatedpartialthromboplastin times were normal,aswere the levelso fv on Willebrand factor (ristocetin cofactor activity) and factor XIII (amidolytic activity).D -dimers were elevateda t 1,800 ng/ml;hyperfibrinolysis wasexcluded(ROTEM™ analysis). Ultrasonographyr evealed a7 1×51×85 mm retroplacental haematoma and anormal-for-dates fetus.
Giventhe active bleeding,immediate dangertomaternofetal well-being, absence of therapeutic alternatives,and virtual certainty of adversefetal outcome from deliveryatthis gestational age,weevaluatedthe off-labeluse of humanrecombinantfactor VIIa (rFVIIa).Aliterature search revealed no reports of rFVIIa useinpregnancy. We estimatedthe thromboticrisk attributable to rFVIIa treatment to be <3%f or the mother and less for the fetus (a literaturesearch and manufacturer'sdata[NovoNordisk, Bagsvaerd, Denmark] provided no evidencethat rFVIIacrossed the placenta), with ar easonable probability of successfulh aemostatic response. After we informedthe patient of the natureof the drug, the potentialcomplications (including thromboembolism and death), and the absence of reported experienceinthis indication, she signed an informed consent form. Based on an unpublished reportobtained from the manufacturerofrFVIIa use (NovoSeven ® ,30µg/kg bodyweight [BW])inapregnant woman with congenitalfactor VII deficiency, and to minimise maternal thrombotic risk,weopted for adose of 20 µg/kg BW (2.4 mg) intravenously(iv). Contractions were managedwith hexoprenaline iv (Gynipral ® ,N ycomed, Waedenswil, Switzerland)a nd fetal lung maturation wasi nducedw ith steroids (betamethasone [Celestone ® ]2×12mgiv; Essex, Lucerne, Switzerland). Active bleeding virtuallyc eased within hours after rFVIIa administration although old blood and blood clots continued to dischargeoverthe following weeks at levels not requiring transfusion. The intrauterine haematomashrank by twothirds (Fig. 1) . Maternal Hb increased to 10.9g/dl after treatment with iv iron (1,200m gi nt otal; Ve nofer ® ,V ifor International, St Gallen, Switzerland)a nd recombinant human erythropoietin (total 20,000 U; Eprex ® ,J anssen-Cilag, Baar, Switzerland). At 31+3 weeks gestation, prematurer upture of membranes prompted antibioticprophylaxis iv.Caesarean section the next daydelivered aclinically healthygirl(1,720 g, 53rd percentile, normal umbilicalarterypH, normal Apgar) whowas admittedtoneonatal intensive care forp rematurity butd id not requirem echanical ventilation. Maternal postpartum recovery wasuneventful, and the patient wasdischarged on day5.Weobservednoside effects fromr FVIIa treatment in eitherm other or fetus. Placentalp athology confirmed the ultrasound diagnosis of partialplacental abruption and revealed an oldextensive retroplacental haematoma,but no signs of chorioamnionitis.
Discussion
Accordingtoacell-basedmodel of coagulation, factor VII plays ak ey rolei ni nitiating haemostasis. Administration of rFVIIa maintains haemostasis by enhancing thrombin generation,leading to the formation of astablefibrin clot (2) . Literature on the obstetric applications of rFVIIa is sparse and mainlylimitedto caser eportsa nd case series on the treatment of postpartum haemorrhage (3).W ew ere aware of the difficulty of gauging thromboembolic risk in off-labelpatients in general and in our patient in particular. ReportsofrFVIIa-related thromboembolic eventshaveincreased dramaticallyinrecent years.O'Connellet al.r eviewed4 31 reports butd ue to data analysis deficiencies failedt op rovide their incidenceo rf requency ( 4) . In on-label treatedp atients, the reported thromboembolic complication (TEC)rateis<1% versus ≥10%inoff-label patients (5). Recent meta-analyses of off-label rFVIIa applications in high-risk sur-gicalp atients report TEC rates of 7.7% (n =1 ,067) and 7.1% (n =507) (6, 7); however, these figuresneed to be setagainst the basalTEC risk of 5.1% and 5.2%, respectively,incontrols without rFVIIatreatment.W eestimatedthe basalTEC risk as being clearlylower thaneitherofthese figures(between0.1 and 0.01% per year) in our 42-year-old patient with no concomitant morbidity or medication, and an egativep ersonal and familyt hromboembolic history.
Pregnancyi sap rothrombotic risk state thatc ompounds relative TEC risk five-fold (8) . The overallvenous thromboembolic risk associated with pregnancy, 1/1,000 to 1/2,000 deliveries (9), furthersupports our estimates, as does the absence of thromboembolism in the series of 79 womentreated with rFVIIa for postpartum haemorrhage (3) . In view of all the above,weestimatedthat the mother'sthrombotic risk attributable to rFVIIa treatment was<3%. To minimise this risk we opted for alow dose of rFVIIa, following Franchini et al.w ho reported (mostly single) doses of 16.7-48 µg/kg body weight (3). We estimated the risk to the fetusaslower still giventhe lowprobability of significant drug transfer across the placenta, based on anegativelit- eratures earch and pathophysiological considerations. Earlier studieshad shown no placental transfer of erythropoietin (molecular weight 30.4k Da), ap rotein considerably smallert han rFVIIa(50 kDa), making it unlikelythat rFVIIacould ever cross the placenta(10). Cade et al. showedthat pretermneonates present lowFVII levels at birth(27%) while mothers have elevated FVIIlevels (11) .
Preterm births account for 75% of perinatal mortality and over halfoflong-term morbidity.Survivors are at increased risk of neuro-developmentalimpairment and gastrointestinal and respiratoryc omplications (12) .P rolongation of pregnancy, as in our case, from2 5t oa tl east3 2w eeks significantlyl owers not only infant mortality buta lso morbidity (bronchopulmonary dysplasia, intraventricularh aemorrhage and necrotizing enterocolitis) (13) .
We concludethat rFVIIawarrants appropriate safety and efficacystudiesasatreatment optionoflastresortfor maternofetal haemorrhagic emergencies unamenable to surgical haemostasis.
